Document is current
Any future updates will be listed below
-
Authors
Tschuck, Juliane https://orcid.org/0000-0002-3144-6027
Padmanabhan Nair, Vidya
Galhoz, Ana
Zaratiegui, Carole
Tai, Hin-Man
Ciceri, Gabriele https://orcid.org/0000-0002-8481-9771
Rothenaigner, Ina
Tchieu, Jason https://orcid.org/0000-0002-9793-9836
Stockwell, Brent R. https://orcid.org/0000-0002-3532-3868
Studer, Lorenz https://orcid.org/0000-0003-0741-7987
Cabianca, Daphne S.
Menden, Michael P. https://orcid.org/0000-0003-0267-5792
Vincendeau, Michelle https://orcid.org/0000-0002-8937-9277
Hadian, Kamyar https://orcid.org/0000-0001-8727-2575
-
Funding
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (435874434, 496872373, 498956525, 497803923)
- License Information
-
More Information
Article History
Received: 16 August 2023
Accepted: 22 August 2024
First Online: 1 September 2024
Competing interests
: B.R.S. is an inventor on patents (granted) and patent applications (pending) involving ferroptosis; co-founded and serves as a consultant to ProJenX, Inc. and Exarta Therapeutics; holds equity in Sonata Therapeutics; serves as a consultant to Weatherwax Biotechnologies Corporation and Akin Gump Strauss Hauer & Feld LLP; and receives sponsored research support from Sumitomo Dainippon Pharma Oncology. L.S. is a scientific founder and paid consultant of BlueRock Therapeutics, a scientific founder of DaCapo Brain Science, and an inventor on patents (granted) owned by MSKCC on the differentiation of human pluripotent stem cells into specific neurons. J.T. and K.H. are inventors on a patent application (pending) involving ferroptosis. The remaining authors declare no competing interests.
